{"log_id": 7810105810581307005, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.000531, "average": 0.991538, "min": 0.869084}, "location": {"width": 1555, "top": 208, "height": 143, "left": 654}, "words": "尽管致畸研究未发现对受孕和胚胎有损害,但动物生殖研究并不一定能预测"}, {"probability": {"variance": 0.001188, "average": 0.984, "min": 0.859774}, "location": {"width": 1644, "top": 301, "height": 147, "left": 558}, "words": "出药物在人体中的反应。由于孕期妇女尚未进行足够的、有良好对照的临床研"}, {"probability": {"variance": 0.000907, "average": 0.987301, "min": 0.866181}, "location": {"width": 1079, "top": 397, "height": 119, "left": 554}, "words": "究,因此除非特别需要,孕妇一般不宜使用比伐芦定"}, {"probability": {"variance": 5.9e-05, "average": 0.994252, "min": 0.983385}, "location": {"width": 143, "top": 503, "height": 54, "left": 554}, "words": "哺乳期"}, {"probability": {"variance": 0.000187, "average": 0.990744, "min": 0.946971}, "location": {"width": 1555, "top": 592, "height": 143, "left": 637}, "words": "尚不清楚比伐芦定是否能经人乳分泌,由于许多药物都能经人乳分泌,因此"}, {"probability": {"variance": 1e-05, "average": 0.996673, "min": 0.988696}, "location": {"width": 839, "top": 685, "height": 106, "left": 544}, "words": "比伐芦定用于哺乳期妇女时必须特别注意"}, {"probability": {"variance": 0.041635, "average": 0.869492, "min": 0.507986}, "location": {"width": 253, "top": 784, "height": 75, "left": 551}, "words": "【儿L童用药】"}, {"probability": {"variance": 0.081173, "average": 0.795543, "min": 0.392624}, "location": {"width": 143, "top": 890, "height": 54, "left": 620}, "words": "比伐"}, {"probability": {"variance": 0.000351, "average": 0.991323, "min": 0.925596}, "location": {"width": 846, "top": 894, "height": 109, "left": 900}, "words": "科中使用的安全性和有效性尚未进行评价"}, {"probability": {"variance": 0.006755, "average": 0.919047, "min": 0.791535}, "location": {"width": 315, "top": 979, "height": 71, "left": 541}, "words": "【老用药"}, {"probability": {"variance": 0.010303, "average": 0.963391, "min": 0.549987}, "location": {"width": 1555, "top": 1075, "height": 150, "left": 609}, "words": "比伐芦定用于行FCI的临床试验中,44%患者的年龄≥65岁,12%的患者>75"}, {"probability": {"variance": 0.003298, "average": 0.977104, "min": 0.67929}, "location": {"width": 1654, "top": 1171, "height": 147, "left": 510}, "words": "岁。年龄大的患者出现出血现象要比年龄小的多,与肝素相比,使用比伐芦定患"}, {"probability": {"variance": 0.000492, "average": 0.986491, "min": 0.914346}, "location": {"width": 565, "top": 1267, "height": 92, "left": 506}, "words": "者的出血事件比使用肝素少"}, {"probability": {"variance": 0.00095, "average": 0.984716, "min": 0.903572}, "location": {"width": 352, "top": 1366, "height": 78, "left": 513}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.017076, "average": 0.950401, "min": 0.360733}, "location": {"width": 1541, "top": 1466, "height": 143, "left": 602}, "words": "在静脉注射完肝素30分钟后或皮下注射完低分子量肝素8小时后可使比"}, {"probability": {"variance": 0.015163, "average": 0.941606, "min": 0.471963}, "location": {"width": 1647, "top": 1558, "height": 147, "left": 493}, "words": "伐芦定。进行了比芦定与血小板抑制剂如阿司匹林、噻氯匹定、氯吡格雷、阿"}, {"probability": {"variance": 0.010965, "average": 0.97219, "min": 0.372841}, "location": {"width": 1654, "top": 1654, "height": 150, "left": 482}, "words": "昔单抗、埃替非巴或替罗非班的相互作用研究,结果显示,上还联合用药没有"}, {"probability": {"variance": 9e-05, "average": 0.992416, "min": 0.97262}, "location": {"width": 431, "top": 1750, "height": 85, "left": 476}, "words": "药效学上的相互作用"}, {"probability": {"variance": 0.027909, "average": 0.829445, "min": 0.662387}, "location": {"width": 68, "top": 1753, "height": 54, "left": 2319}, "words": "08"}, {"probability": {"variance": 0.013282, "average": 0.957452, "min": 0.448167}, "location": {"width": 1561, "top": 1849, "height": 147, "left": 565}, "words": "从药物作用机理可知,比伐芦定与抗凝药物《开素、华法林、血小板球蛋白"}, {"probability": {"variance": 6e-06, "average": 0.996588, "min": 0.994129}, "location": {"width": 113, "top": 1880, "height": 47, "left": 2332}, "words": "2号"}, {"probability": {"variance": 0.015185, "average": 0.956574, "min": 0.360226}, "location": {"width": 1657, "top": 1945, "height": 143, "left": 465}, "words": "或血小板抑制剂)联合月药可能会增加出血的危险,在任何情况下,当比芦定"}, {"probability": {"variance": 0.002404, "average": 0.98052, "min": 0.758466}, "location": {"width": 1589, "top": 2041, "height": 147, "left": 465}, "words": "与血小板抑制剂抗凝药物联合用药时,要经常监测临床和生物学的凝血参数"}, {"probability": {"variance": 0.00088, "average": 0.977323, "min": 0.920759}, "location": {"width": 253, "top": 2144, "height": 65, "left": 476}, "words": "【药物过量"}, {"probability": {"variance": 0.015529, "average": 0.929179, "min": 0.57775}, "location": {"width": 1565, "top": 2243, "height": 143, "left": 544}, "words": "单次静推超过7.5 mg/kg剂量没有发现出血或其他不良反应,停止使用比伐芦"}, {"probability": {"variance": 0.011197, "average": 0.95917, "min": 0.579621}, "location": {"width": 1657, "top": 2336, "height": 147, "left": 445}, "words": "定后由于代谢的作用,体内抗凝血作用会逐渐降低使用过量时,应立刻停止使"}, {"probability": {"variance": 0.008205, "average": 0.952249, "min": 0.636909}, "location": {"width": 1661, "top": 2432, "height": 150, "left": 438}, "words": "用比伐芦定,并密切观察患者有无出血征兆。比伐芦定可以通过血液透析清除"}, {"probability": {"variance": 0.001454, "average": 0.972477, "min": 0.874831}, "location": {"width": 1102, "top": 2531, "height": 119, "left": 459}, "words": "见药代动力学),前还没有发现比伐芦定的解毒药"}, {"probability": {"variance": 0.00607, "average": 0.957087, "min": 0.801529}, "location": {"width": 256, "top": 2630, "height": 75, "left": 448}, "words": "【药理理】"}, {"probability": {"variance": 0.014978, "average": 0.947921, "min": 0.374624}, "location": {"width": 1565, "top": 2726, "height": 147, "left": 517}, "words": "比伐芦定是凝血酶的直接抑制剂,与游离血栓上凝血酶的催化位点和阴高"}, {"probability": {"variance": 0.015264, "average": 0.953715, "min": 0.351613}, "location": {"width": 1654, "top": 2822, "height": 150, "left": 424}, "words": "子外结合位点特异结合起抑制作用、凝血酶是一种丝氨酸蛋白酶,在直形成过"}, {"probability": {"variance": 0.004068, "average": 0.978406, "min": 0.652619}, "location": {"width": 1654, "top": 2918, "height": 154, "left": 417}, "words": "程中起重要的作用,它首先将纤维蛋白原分解为纤维蛋白单体,然后将凝血因"}, {"probability": {"variance": 0.020432, "average": 0.907541, "min": 0.45993}, "location": {"width": 1654, "top": 3017, "height": 150, "left": 414}, "words": "子XIII激活为XII,使纤维蛋白之间共价连接成为稳定的网架,形成血检,凝"}, {"probability": {"variance": 0.023856, "average": 0.925716, "min": 0.422615}, "location": {"width": 1657, "top": 3113, "height": 150, "left": 404}, "words": "血同时还可激活凝血酶因子V和YII,进一步促进凝血酶的形成还可邀活血"}], "language": 3}